Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)

Core Insights - The study published in The Lancet Diabetes & Endocrinology highlights the clinical advantages of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, in reducing life-threatening cardiovascular outcomes compared to empagliflozin [2][3] - Sotagliflozin demonstrated a significant reduction in major adverse cardiovascular events (MACE), myocardial infarction (MI), and stroke among patients with type 2 diabetes (T2D), chronic kidney disease (CKD), and high cardiovascular risk [3][5] Study Findings - The secondary analysis of the SCORED trial revealed that patients receiving sotagliflozin had a lower rate of MACE outcomes at 4.8 events per 100 person-years compared to 6.3 events per 100 person-years in the placebo group, with a hazard ratio of 0.77 [4][5] - The study also found that sotagliflozin reduced the rate of MI to 1.8 events per 100 person-years versus 2.7 events per 100 person-years in the placebo group, with a hazard ratio of 0.68 [5] - Additionally, the rate of stroke was reduced to 1.2 events per 100 person-years in the sotagliflozin group compared to 1.8 events per 100 person-years in the placebo group, with a hazard ratio of 0.66 [5] Company Overview - Lexicon Pharmaceuticals is focused on pioneering medicines that transform patients' lives, utilizing its Genome5000™ program to discover therapeutic targets [9] - The company has a pipeline of drug candidates in various stages of development, addressing conditions such as neuropathic pain, hypertrophic cardiomyopathy, and obesity [9]